MX2019014831A - Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor. - Google Patents

Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor.

Info

Publication number
MX2019014831A
MX2019014831A MX2019014831A MX2019014831A MX2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A
Authority
MX
Mexico
Prior art keywords
methods
administering
diabetic patients
pcsk9 inhibitor
treating hyperlipidemia
Prior art date
Application number
MX2019014831A
Other languages
Spanish (es)
Inventor
Bujas-Bobanovic Maja
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Priority claimed from PCT/IB2018/054182 external-priority patent/WO2018225041A1/en
Publication of MX2019014831A publication Critical patent/MX2019014831A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided are methods for treating high cardiovascular risk patients with hypercholesterolemia and type 1 or type 2 diabetes mellitus receiving insulin therapy. These methods generally comprise administering to a patient a pharmaceutical composition comprising an antibody or antigen binding fragment, thereof, which specifically binds hPCSK9 antibody, in combination with insulin therapy.
MX2019014831A 2017-06-09 2018-06-09 Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor. MX2019014831A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762517672P 2017-06-09 2017-06-09
US201762532162P 2017-07-13 2017-07-13
EP18305565 2018-05-04
PCT/IB2018/054182 WO2018225041A1 (en) 2017-06-09 2018-06-09 Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor

Publications (1)

Publication Number Publication Date
MX2019014831A true MX2019014831A (en) 2020-02-13

Family

ID=62815099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014831A MX2019014831A (en) 2017-06-09 2018-06-09 Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor.

Country Status (9)

Country Link
EP (1) EP3634469A1 (en)
JP (2) JP2020522544A (en)
KR (1) KR20200026826A (en)
CN (1) CN110913889A (en)
AU (1) AU2018280567A1 (en)
CA (1) CA3066317A1 (en)
IL (1) IL271212A (en)
MX (1) MX2019014831A (en)
TW (2) TW202310872A (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476796A (en) 2011-01-28 2013-12-25 赛诺菲 Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087305A1 (en) 2011-07-28 2014-03-12 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
CN107922507B (en) 2015-08-18 2022-04-05 瑞泽恩制药公司 anti-PCSK 9 inhibitory antibodies for treating hyperlipidemic patients receiving lipoprotein apheresis
CN113876956B (en) * 2020-07-01 2023-07-04 陈敏 Application of PCSK9 inhibitor in preparation of product for promoting skin pigmentation
CN114525258A (en) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell expressing PCSK9 blocker or derivative thereof and application
CN118076736A (en) * 2021-09-30 2024-05-24 北京安龙生物医药有限公司 Targeting oligonucleotides for treating PCSK 9-related diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (en) * 2008-12-15 2020-08-27 Regeneron Pharma High Affinity Human Antibodies to PCSK9
JP2017528427A (en) * 2014-07-16 2017-09-28 サノフィ・バイオテクノロジー Method for treating a patient having heterozygous familial hypercholesterolemia (heFH)
PL3169362T3 (en) * 2014-07-16 2020-12-28 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia
CN107922507B (en) * 2015-08-18 2022-04-05 瑞泽恩制药公司 anti-PCSK 9 inhibitory antibodies for treating hyperlipidemic patients receiving lipoprotein apheresis

Also Published As

Publication number Publication date
IL271212A (en) 2020-01-30
EP3634469A1 (en) 2020-04-15
CN110913889A (en) 2020-03-24
AU2018280567A1 (en) 2020-01-23
JP2023123842A (en) 2023-09-05
RU2019144346A3 (en) 2021-10-13
RU2019144346A (en) 2021-07-09
TW202310872A (en) 2023-03-16
CA3066317A1 (en) 2018-12-13
JP2020522544A (en) 2020-07-30
KR20200026826A (en) 2020-03-11
TW201904608A (en) 2019-02-01

Similar Documents

Publication Publication Date Title
MX2019014831A (en) Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor.
AU2018263862A1 (en) Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof
UA117570C2 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
MX2019011117A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof.
AR104812A1 (en) THERAPEUTIC COMBINATIONS AND METHODS TO TREAT NEOPLASIAS
CY1118616T1 (en) LIXISENATIDE AS ADDITIONAL TREATMENT IN BASIC INSULIN IN TYPE 2 DIABETES
EA201692282A1 (en) COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS, CONTAINING INSULIN AND GLOP-1 / GLUCAGON DOUBLE AGONIST
SG195275A1 (en) A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
CY1111595T1 (en) MODIFICATION OF PIRPHENIDONINE TREATMENT FOR PATIENTS WITH NON-PHYSIOLOGICAL US FUNCTIONING
MX2010006823A (en) Methods for the treatment of gout.
MX2007012702A (en) Use of cd25 antibodies in immunotherapy.
UA117096C2 (en) Polypeptides binding to human complement c5
AR082312A1 (en) A PHARMACEUTICAL COMBINATION COMPOSITION TO TREAT DIABETES AND METABOLIC DISORDERS
MX2019014375A (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof.
MX2023000796A (en) Pharmaceutical composition, methods for treating and uses thereof.
WO2018116267A3 (en) Methods of treatment with anti-factor xi/xia antibodies
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
MX2022008471A (en) Anti-angptl3 antibody and use thereof.
MX2009003039A (en) Use of an anti-cd151 antibody in the treatment of cancer.
MX2020008718A (en) Bcma-binding antibodies and uses thereof.
BR112016023011A2 (en) gastric cancer treatment
MX2018013729A (en) New dapagliflozin crystal form and preparation method and use thereof.
CL2021000444A1 (en) Methods to reduce the risk of diabetes in patients treated for diseases related to high cholesterol.
EP4306128A3 (en) Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
PH12020550066A1 (en) METHOD FOR TREATING TNFa-RELATED DISEASE